for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied Genetic Technologies Corp

AGTC.OQ

Latest Trade

3.06USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.26

 - 

7.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.06
Open
--
Volume
--
3M AVG Volume
3.38
Today's High
--
Today's Low
--
52 Week High
7.45
52 Week Low
2.26
Shares Out (MIL)
18.22
Market Cap (MIL)
55.75
Forward P/E
-1.33
Dividend (Yield %)
--

Latest Developments

More

AGTC And Otonomy Announce Strategic Collaboration To Develop, Commercialize Gene Therapy For Congenital Hearing Loss

AGTC Posts Fourth Quarter Results

Applied Genetic Technologies Corp QTRLY Earnings Per Share $0.63

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Applied Genetic Technologies Corp

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Industry

Biotechnology & Drugs

Contact Info

14193 Nw 119Th Terrace, Suite #10

+1.386.4622204

https://www.agtc.com/

Executive Leadership

Scott Koenig

Chairman of the Board

Susan B. Washer

President, Chief Executive Officer, Director

William A. Sullivan

Chief Financial Officer

Matthew Feinsod

Executive Vice President - lobal Strategy and Development

Mark S. Shearman

Chief Scientific Officer

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

0.020

2018

-1.180

2019

-0.110

2020(E)

-2.302
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.34
Price To Book (MRQ)
0.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-2.11
Return on Equity (TTM)
-1.87

Latest News

Latest News

BRIEF-Applied Genetic Technologies Qtrly Rev Fell To $3.6 Mln

* Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa

* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:

BRIEF-Applied Genetic Technologies Reports Quarterly Loss Per Share Of ‍$ 0.29​

* APPLIED GENETIC TECHNOLOGIES QTRLY REVENUE $4.9 MILLION VERSUS $10.9 MILLION

BRIEF-Applied Genetic Technologies Reports Qtrly Loss Per Share Of ‍$0.29​

* AS OF DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $119.7 MILLION

BRIEF-Applied Genetic posts qtrly ‍net loss of $0.08​ per share

* Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million

BRIEF-Applied Genetic Technologies reports Q4 revenue of $8.3 mln

* Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S

BRIEF-AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

* AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

BRIEF-AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa

* AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene

BRIEF-AGTC announces FDA orphan drug designation for therapy to treat X-linked retinitis pigmentosa

* AGTC announces U.S. FDA orphan drug designation for gene therapy to treat X-linked retinitis pigmentosa Source text for Eikon: Further company coverage:

BRIEF-AGTC appoints William Sullivan as chief financial officer

* AGTC appoints William Sullivan as chief financial officer, Andrew Ashe named general counsel

BRIEF-Applied Genetic Technologies updates on clinical development of AGTC-402

* Enabling study data published in human gene therapy clinical development support clinical development of AGTC-402 for the treatment of CNGA3-deficient achromatopsia

BRIEF-AGTC announces topline safety data for X-linked retinoschisis phase 1/2 study

* AGTC announces topline safety data for X-linked retinoschisis phase 1/2 study

BRIEF-Applied Genetic Technologies quarterly revenue $8.4 million

* Applied Genetic Technologies -Total revenue for three months ended March 31, 2017 was $8.4 million compared to $12.0 million generated during same period in 2016

BRIEF-Applied Genetic Technologies quarterly revenue $10.9 million versus $12.2 million

* Applied Genetic Technologies says total revenue for three months ended Dec 31, 2016 was $10.9 million compared to $12.2 million during same period in 2015

BRIEF-AGTC and Bionic Sight report strategic collaboration to develop an optogenetic therapy and device

* AGTC and Bionic Sight announce strategic collaboration to develop an optogenetic therapy and device for visual deficits and blindness Source text for Eikon: Further company coverage:

BRIEF-Applied Genetic Technologies quarterly EPS $0.20

* Quarterly revenue $11.8 million versus $11.1 million Source text for Eikon: Further company coverage:

BRIEF-AGTC files investigational NDA for treatment of achromatopsia

* AGTC files investigational new drug application for the treatment of Achromatopsia caused by mutations in the CNGA3 gene Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up